Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells

Nakano, Tadashi; Inoue, Ryo; Kimura, Tohru; Suzumura, Hirotaka; Tanino, Tomihiko; Yamazaki, Yoshio; Yoshikawa, Keiji; Tatemichi, Masayuki

doi:10.1007/s12325-016-0373-y

Cited by 14 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 Similarly, the ECD was reported not to vary significantly during the 48-week follow-up period in cases using latanoprost. 16 Kwon et al 17 that glaucoma patients using BB or prostaglandin analog had corneal ECDs similar to those of nonmedicated individuals. The authors thought that the drug concentration in the aqueous humor did not reach the toxic levels enough to reduce the number of endothelial cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Do topical antiglaucoma drugs affect the cornea?

Güneş

Öztürk

Özen

2021

European Journal of Ophthalmology

View full text Add to dashboard Cite

To investigate effects of beta blocker (BB; timolol or betaxolol), latanoprost, and latanoprost-timolol combination (LTC) drugs on corneal endothelial cell density (ECD) and central corneal thickness (CCT) in primary open-angle glaucoma (POAG) patients. Sixty-one patients in BB group, 64 patients in latanoprost group, 59 patients in LTC group, and 58 healthy cases in control group were included. Intraocular pressures (IOP), ECDs, and CCTs of groups were recorded at initial (pre-treatment) period, first and third years after treatment, and comparisons were done. In groups, changes of ECDs according to time were not significant ( p > 0.05). In BB and control groups, changes of CCTs according to time were not significant ( p > 0.05). In latanoprost and LTC groups, CCTs in both first and third years were significantly thinner than initial CCTs ( p = 0.039 for latanoprost, p = 0.041 for LTC at first year; p = 0.018 for latanoprost, p = 0.032 for LTC at third year). In latanoprost and LTC groups, CCTs of patients using drugs for 1 year were similar to those of patients using drugs for 3 years ( p > 0.05). In our study, uses of BB, latanoprost or LTC did not affect ECD. BB drugs had no effect on CCT. Although latanoprost and LTC appeared to reduce CCT at 3-year follow-up from the statistical point of view, this 8–10 μm difference in CCT was not clinically significant.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This study was performed with approval of University of Health Sciences, Izmir Tepecik Training and Research Hospital's Medical Research Ethical Committee (approval number: 2019/ [16][17][18][19][20][21][22] and in line with ethical principles of Declaration of Helsinki. Written consent forms were received from all participants.…”

Section: Methodsmentioning

confidence: 99%

Do topical antiglaucoma drugs affect the cornea?

Güneş

Öztürk

Özen

2021

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Several randomized clinical trials reported that the non-fixed combination of latanoprost 0.005% and brinzolamide 1% exerts a better IOP reducing effect than latanoprost monotherapy ( Shoji et al, 2005 ; Nakamoto and Yasuda, 2007 ; Nakano et al, 2016 ). A comparative study demonstrated that LBz-nFC provides a more sustained IOP lowering effect than LT-nFC.…”

Section: Topical Non-fixed Combination Of Two Agentsmentioning

confidence: 99%

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Wang

Cao²,

Jiang³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Glaucoma is one of the most common causes of blindness, thus seriously affecting people’s health and quality of life. The topical medical therapy is as the first line treatment in the management of glaucoma since it is inexpensive, convenient, effective, and safe. This review summarizes and compares extensive clinical trials on the topical medications for the treatment of glaucoma, including topical monotherapy agents, topical fixed-combination agents, topical non-fixed combination agents, and their composition, mechanism of action, efficacy, and adverse effects, which will provide reference for optimal choice of clinical medication. Fixed-combination therapeutics offer greater efficacy, reliable security, clinical compliance, and tolerance than non-fixed combination agents and monotherapy agents, which will become a prefer option for the treatment of glaucoma. Meanwhile, we also discuss new trends in the field of new fixed combinations of medications, which may better control IOP and treat glaucoma.

show abstract

“…BLZ is a non-competitive, effective, and very specific carbonic anhydrase inhibitor for the treatment of glaucoma. 3 Clinically, BLZ ocular suspension was mainly used as a first-line antiglaucoma medication following a dosage of one drop each time and twice a day (preferably three times a day). However, its use has been limited by a number of factors, including systemic adverse events (taste aversion), ocular adverse events (eye burning sensation and stinging pain), and relatively high prices.…”

Section: Introductionmentioning

confidence: 99%

A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation

Jin¹,

Zhou²

2018

DDDT

View full text Add to dashboard Cite

BackgroundThe aim of the study was to develop a sustained ocular delivery of brinzolamide (BLZ) based on gellan gum.MethodsThe formulations were characterized for clarity, gelling capacity, rheological studies, pH, drug content, and in vitro drug-release behavior. In vivo rabbit eye irritation test was conducted to evaluate irritation of the BLZ gel drug-delivery system. The prepared BLZ formulations were then investigated in vivo and compared with commercially available BLZ eyedrops with regard to pharmacodynamics.ResultsThe results showed that the optimum concentration of gellan gum was 0.25% w/v; the prepared liquid was converted into a flowing gel after the addition of simulated tear fluid. In vitro release profiles showed that the release of BLZ from the in situ gel exhibited sustained characteristics. Draize test results showed that BLZ in situ gels did not stimulate signs of eye tissue activity and were less irritating than BLZ solutions and commercial Azopt.ConclusionThe results of pharmacodynamics implied that the novel preparation of BLZ in situ gel effectively prolonged the intraocular pressure-lowering effect after administration.

show abstract

Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells

Abstract: Patients treated with LT + BR showed significant IOP reduction. However, the use of brinzolamide in addition to latanoprost had no influence on CECs during the one-year follow-up period.

Cited by 14 publications

References 14 publications

Do topical antiglaucoma drugs affect the cornea?

Do topical antiglaucoma drugs affect the cornea?

Topical Medication Therapy for Glaucoma and Ocular Hypertension

A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation

Contact Info

Product

Resources

About